iGlarLixi Safe and Effective in Inadequately Controlled T2D

A once-daily injectable therapy of a fixed-ratio combination of insulin glargine and lixisenatide improved glycemic control, with low rates of hypoglycemia, in people with T2D in a real-world setting.

Related Keywords

Qatar , United States , American , Rayaza Malik , , Qatar Foundation , Research Division , American Diabetes , European Association , Weill Cornell Medicine Qatar , Education City , Diabetes Mellitus Type 2 , Iabetes Mellitus Type Ii , Type 2 Diabetes , Ype 2 Dm , T2dm , 2d , Hypoglycemia , Board Certification , Boards , Oard Recertification , Metabolism , Etabolic , Office Visits , Patient Visits , Receptors , Obesity , Bese ,